Evidence map›Paper›PMID 32674689›Full record

ArticleInternational journal of immunopathology and pharmacology

Protective effect of resveratrol on estrogen deficiency-induced osteoporosis though attenuating NADPH oxidase 4/nuclear factor kappa B pathway by increasing miR-92b-3p expression.

Ye Zhang, Ming-Wei Liu, Yun He, Ning Deng, Yan Chen, Jiecong Huang, Wei Xie

Abstract read
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. 7-Hydroxyflavone Mitigates OsteoporosisCurrent topics in medicinal chemistry · 2025
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ye ZhangDepartment of Traditional Chinese Medicine, The Third People's Hospital of Yunnan Province, Kunming, China.
Ming-Wei LiuDepartment of Emergency Medicine, First Affiliated Hospital of Kunming Medical University, Kunming, China.ORCID https://orcid.org/0000-0002-3728-2350
Yun HeDepartment of Orthopedics, Calmett Hospital & The First Hospital of Kunming, Kunming, China.
Ning DengSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
Yan ChenNormal Human Anatomy and Histological Embryology Department, Yunnan University of Traditional Chinese Medicine, Kunming, China.
Jiecong HuangDepartment of Encephalopathy, Guangzhou Conghua Hospital of Traditional Chinese Medicine, Guangzhou, China.
Wei XieSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0002-0694-2731

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionResveratrol (RES) exhibits estrogen-like effects and has potential applications to treatment of osteoporosis caused by estrogen deficiency; however, the specific mechanism of action of RES remains unclear. Here, we examined the therapeutic effects of RES on ovariectomized (OVX) rats with osteoporosis and determined the underlying mechanism.

methodsWe established an OVX rat model to study osteoporosis caused by estrogen deficiency. The treatment groups were given orally with RES (50, 100, and 200 mg/day), the estrogen group received 0.8 mg/kg E2 daily via oral route, and the sham-operated and control groups received an equivalent dose of sodium carboxymethylcellulose orally. After 12 weeks of treatment, we used real-time quantitative polymerase chain reaction (PCR) and Western blot analysis to measure the gene and protein expression of miR-92b-3p, Nox4, NF-κBp65, IκB, BMP2, Smad7, and RUNX-2 in bone tissues. Right femur structural parameters were evaluated by micro-CT. Dual-energy X-ray 4500 W was used to determine systemic bone mineral density (BMD). Enzyme-linked immunosorbent assay (ELISA) kits were used to determine the serum levels of bone alkaline phosphatase (BALP), osteoprotegerin (OPG), anti-tartrate acid phosphatase-5b (PTRA5b), and carboxylated terminal peptide (CTX-I). The rat femoral bone specimens were stained using hematoxylin and eosin for pathological examination.

resultsWe observed increased levels of serum estrogen in both ovaries, elevated miR-92b-3p levels in bone tissues, reduced levels of Nox4, NF-κBp65, p-IκB-a, and cathepsin K, and elevated gene and protein expression of BMP2, Smad7, and RUNX-2 in the OVX rat model of osteoporosis after treatment with RES. Elevated levels of BALP, OPG, ALP, and BMD along with reduced levels of TRAP-5b and CTX-I were also observed. The structural model index (SMI) and the trabecular space (Tb. Sp) decreased, while the trabecular thickness (Tb. Th), bone volume fraction (BV/TV), trabecular number (Tb.N), and tissue bone density (Conn.D) increased, thereby improving osteoporosis induced by estrogen deficiency in both ovaries.

conclusionCathepsin K expression and Nox4/NF-κB signaling pathway were suppressed by the elevated expression of miR-92b-3p. This inhibition was pivotal in the protective effect of RES against osteoporosis induced by estrogen deficiency in both ovaries. Thus, RES efficiently alleviated osteoporosis induced by estrogen deficiency in rats.

Indexed as

AnimalsBone DensityBone Density Conservation AgentsBone RemodelingCathepsin KCells, CulturedDisease Models, AnimalEstrogensFemaleFemurHumansMesenchymal Stem CellsMicroRNAsNADPH Oxidase 4NF-kappa BOsteoporosis, PostmenopausalBone Density Conservation AgentsCathepsin KCtsk protein, ratEstrogensMicroRNAsMIRN92 microRNA, ratNADPH Oxidase 4NF-kappa BNox4 protein, ratResveratrolmiR-92b-3pNF-κBp65Nox4osteoporosisresveratrol

Identifiers

PMID32674689
PMCPMC7370339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.